Jim Lambert

Jim Lambert is currently the Executive Director of Financial Reporting and Controls at Autolus Ltd., a biopharmaceutical company focusing on developing next-generation programmed T cell therapies for cancer treatment. Prior to this role, Jim served as the Executive Director Finance at Precigen, a subsidiary of Intrexon Corporation, which specializes in synthetic biology to alleviate disease. Jim also held the position of Vice President of Accounting & Finance at GenVec, a clinical-stage biopharmaceutical company. With a background in accounting and economics, Jim has also worked at companies such as Sigma Tau Pharmaceuticals, Stone Street Capital, OncorMed, and Blue Cross Blue Shield.